OomenAG, BleekerEA, BosPM, et al.Grouping and read-across approaches for risk assessment of nanomaterials. Int J Environ Res Public Health, 2015:12; 13415–13434.
2.
BurdenN, AschbergerK, ChaudhryQ, et al.Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?. Regul Toxicol Pharmacol, 2017:91; 257–266.
3.
WiemannM, VennemannA, SauerUG, et al.An in vitro alveolar macrophage assay for predicting the short-term inhalation toxicity of nanomaterials. J Nanobiotechnology, 2016:14; 16.
4.
Interagency Coordinating Committee on the Validation of Alternative Methods.. A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States. January. 2018. https://ntp.niehs.nih.gov/pubhealth/evalatm/natl-strategy/index.html (last accessed Mar. 12, 2018).
5.
ClippingerAJ, AllenD, JarabekAM, et al.Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicol In Vitro, 2018:48; 53–70.
6.
StricklandJ, ClippingerAJ, BrownJ, et al.Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies. Regul Toxicol Pharmacol, 2018:94; 183–196.
7.
BehrsingH, HillE, RaabeH, et al.In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use. Altern Lab Anim, 2017:45; 117–158.
